ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NIM Norwood Imm.

0.50
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Norwood Imm. LSE:NIM London Ordinary Share AU000A0CANX1 ORD SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.50 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Norwood Immunology Share Discussion Threads

Chat Pages: 1
DateSubjectAuthorDiscuss
22/5/2008
10:41
I'm not actually a doctor

I'd imagine you're the latest name from one of my 'friends' on another thread. However....

In this case, its exploiting the body's own immune system to effect therapeutic benefits. But immunology is a wider field relating to the immune system in general.

the_doctor
22/5/2008
10:07
As a doctor, would you please explain to me what immunology is?

tia.

gale dribble
22/5/2008
09:51
bump, fell off my list
the_doctor
25/11/2007
09:34
There could be some subsequent interest in use of their virosomes to deliver RNAi...

: J Liposome Res. 2007;17(1):39-47. Links
Cellular delivery of siRNA mediated by fusion-active virosomes.Huckriede A, De Jonge J, Holtrop M, Wilschut J.
Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

RNA interference is expected to have considerable potential for the development of novel specific therapeutic strategies. However, successful application of RNA interference in vivo will depend on the availability of efficient delivery systems for the introduction of small-interfering RNA (siRNA) into the appropriate target cells. This paper focuses on the use of reconstituted viral envelopes ("virosomes"), derived from influenza virus, as a carrier system for cellular delivery of siRNA. Complexed to cationic lipid, siRNA molecules could be efficiently encapsulated in influenza virosomes. Delivery to cultured cells was assessed on the basis of flow cytometry analysis using fluorescently labeled siRNA. Virosome-encapsulated siRNA directed against Green Fluorescent Protein (GFP) inhibited GFP fluorescence in cells transfected with a plasmid encoding GFP or in cells constitutively expressing GFP. Delivery of siRNA was dependent on the low-pH-induced membrane fusion activity of the virosomal hemagglutinin, supporting the notion that virosomes introduce their encapsulated siRNA into the cell cytosol through fusion of the virosomal membrane with the limiting membrane of cellular endosomes, after internalization of the virosomes by receptor-mediated endocytosis. It is concluded that virosomes represent a promising carrier system for cellular delivery of siRNA in vitro as well as in vivo.


Norwood's virosome patents

Patents:
US
20060228376
EP1594466


Final rejection recieved in the US on 11 Nov 07


Examiner's issues to be resolved:
- can the patent be limited to 1-8 carbon atoms, when the original application was 1-12 - does this matter and why have they limited in this way (presumably explained in an earlier document that I've not read yet)

- substituting detergent for short-chain phospholipid could have been anticipated by Johnson et al and Hauser

########

Might be worth a punt when the patent issues are sorted out in 6 months time
& if they've sorted out further finances

the_doctor
07/11/2007
11:22
Ah, they raised funds earlier!
A years' cash left for now.

Would be interesting to see if they have any catalysts that could bring in income over the next year?
Furthermore, if they have valued IP, they could be taken out?

(I dont hold this stock by the way)

"On 27 November 2006, the Group completed a #6.6m ($16.8m) fundraising before
expenses, with the issue and placement of 55,000,000 ordinary shares"

the_doctor
21/8/2007
10:17
No fundraising yet... I was thinking of calling the company to ask what their plan is?
the_doctor
11/7/2007
09:01
Not sure why these guys have been out acquiring other companies when they dont have much cash. May have been bargains, but I think a fundraising may be coming shortly?
the_doctor
11/4/2007
16:00
I think someone should have told them "prevention better than the cure"
hi-there
08/8/2006
15:20
Over 10 million shares dumped. Anyone got any info?
justaminute.com
Chat Pages: 1

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com